Mechanism for alternating access in neurotransmitter transporters LR Forrest, YW Zhang, MT Jacobs, J Gesmonde, L Xie, BH Honig, ... Proceedings of the National Academy of Sciences 105 (30), 10338-10343, 2008 | 405 | 2008 |
Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter MT Jacobs, YW Zhang, SD Campbell, G Rudnick Journal of biological chemistry 282 (40), 29441-29447, 2007 | 145 | 2007 |
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy JY Spiegel, S Dahiya, MD Jain, J Tamaresis, LJ Nastoupil, MT Jacobs, ... Blood, The Journal of the American Society of Hematology 137 (13), 1832-1835, 2021 | 98 | 2021 |
Genomic landscape of appendiceal neoplasms CSP Ang, JP Shen, CJ Hardy-Abeloos, JK Huang, JS Ross, VA Miller, ... JCO Precision Oncology 2, 1-18, 2018 | 61 | 2018 |
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia MM Berrien-Elliott, JA Foltz, DA Russler-Germain, CC Neal, J Tran, ... Science translational medicine 14 (633), eabm1375, 2022 | 60 | 2022 |
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy MM Berrien-Elliott, M Becker-Hapak, AF Cashen, M Jacobs, P Wong, ... Blood, The Journal of the American Society of Hematology 139 (8), 1177-1183, 2022 | 59 | 2022 |
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium Y Wang, P Jain, FL Locke, MJ Maurer, MJ Frank, JL Munoz, S Dahiya, ... Journal of clinical oncology 41 (14), 2594-2606, 2023 | 57 | 2023 |
Allogeneic natural killer cell therapy MM Berrien-Elliott, MT Jacobs, TA Fehniger Blood 141 (8), 856-868, 2023 | 57 | 2023 |
Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR … MD Jain, MT Jacobs, LJ Nastoupil, JY Spiegel, G Feng, Y Lin, ... Blood 134, 245, 2019 | 57 | 2019 |
Memory-like differentiation enhances NK cell responses to melanoma ND Marin, BA Krasnick, M Becker-Hapak, L Conant, SP Goedegebuure, ... Clinical Cancer Research 27 (17), 4859-4869, 2021 | 43 | 2021 |
A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport LK Henry, H Iwamoto, JR Field, K Kaufmann, ES Dawson, MT Jacobs, ... Journal of Biological Chemistry 286 (35), 30823-30836, 2011 | 37 | 2011 |
Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium Y Wang, P Jain, FL Locke, J Munoz, MJ Maurer, A Beitinjaneh, MJ Frank, ... Blood 138, 744, 2021 | 27 | 2021 |
The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation MT Jacobs, M Olson, BP Ferreira, R Jin, R Hachem, D Byers, C Witt, ... American Journal of Transplantation 20 (2), 589-592, 2020 | 23 | 2020 |
CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy MY Kim, ML Cooper, MT Jacobs, JK Ritchey, J Hollaway, TA Fehniger, ... JCI insight 6 (16), 2021 | 19 | 2021 |
Use of low-frequency driver mutations detected by cell-free circulating tumor DNA to guide targeted therapy in non–small-cell lung cancer: a multicenter case series MT Jacobs, NA Mohindra, L Shantzer, IL Chen, H Phull, W Mitchell, ... JCO Precision Oncology 2, 1-10, 2018 | 13 | 2018 |
T-BET and EOMES sustain mature human NK cell identity and antitumor function P Wong, JA Foltz, L Chang, CC Neal, T Yao, CC Cubitt, J Tran, ... The Journal of Clinical Investigation 133 (13), 2023 | 11 | 2023 |
Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD M McKenna, N Epperla, A Ghobadi, J Liu, A Lazaryan, U Ibrahim, ... British journal of haematology 202 (2), 248-255, 2023 | 8 | 2023 |
Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US lymphoma CAR-T consortium MT Jacobs, MD Jain, F Gao, LJ Nastoupil, JY Spiegel, Y Lin, S Dahiya, ... Clinical Lymphoma Myeloma and Leukemia 22 (10), 753-759, 2022 | 8 | 2022 |
Long-term outcomes of patients with large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel: results from the US lymphoma CAR-T cell consortium JY Spiegel, MD Jain, L Nastoupil, J Tamaresis, A Ghobadi, Y Lin, ... Blood 138, 3826, 2021 | 6 | 2021 |
A conserved asparagine residue in TM1 of the serotonin transporter dictates chloride-coupled neurotransmitter transport LK Henry, H Iwamoto, JR Field, K Kaufmann, ES Dawson, MT Jacobs, ... J Biol Chem 286, 30823-30836, 2011 | 5 | 2011 |